<?xml version="1.0" encoding="UTF-8"?>
<rr:ResultsReport xmlns:rr="http://integration.foundationmedicine.com/reporting" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd">
  <rr:CustomerInformation>
    <rr:ReferenceID>01-2023-00030235</rr:ReferenceID>
    <rr:CSN />
    <rr:TRF>ORD-1648390-01</rr:TRF>
    <rr:MRN>7948825</rr:MRN>
    <rr:PhysicianId>109266</rr:PhysicianId>
    <rr:NPI />
  </rr:CustomerInformation>
  <rr:ResultsPayload>
    <FinalReport xmlns:xsd="http://www.w3.org/2001/XMLSchema" StagingId="1334248" clinicalId="1335595" xsi:noNamespaceSchemaLocation="http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd">
      <Application>
        <ApplicationSettings>
          <ApplicationSetting>
            <Name>Statement</Name>
            <Value />
          </ApplicationSetting>
        </ApplicationSettings>
      </Application>
      <DemographicCorrectionDate />
      <ReportId>ORD-1648390-01</ReportId>
      <SampleName>US1572225.01</SampleName>
      <Version>0</Version>
      <Sample>
        <FM_Id>ORD-1648390-01</FM_Id>
        <SampleId>US1572225.01</SampleId>
        <BlockId>S112-25343 G (PF23078)</BlockId>
        <TRFNumber>ORD-1648390-01</TRFNumber>
        <TestType>FoundationOne CDX</TestType>
        <SpecFormat>Slide Deck</SpecFormat>
        <ReceivedDate>2023-06-09</ReceivedDate>
        <processSites>
          <processSite address="150 Second St., 1st Floor, Cambridge, MA 02141" cliaNumber="22D2027531" locationID="1" locationName="Cambridge" processID="1" processName="LC" />
          <processSite address="150 Second St., 1st Floor, Cambridge, MA 02141" cliaNumber="22D2027531" locationID="1" locationName="Cambridge" processID="1" processName="Extracted DNA" />
        </processSites>
      </Sample>
      <PMI>
        <ReportId>ORD-1648390-01</ReportId>
        <MRN>7948825</MRN>
        <FullName>Lin Chung, Shu Ying</FullName>
        <FirstName>Shu Ying</FirstName>
        <LastName>Lin Chung</LastName>
        <SubmittedDiagnosis>Skin melanoma</SubmittedDiagnosis>
        <Gender>Female</Gender>
        <DOB>1952-04-20</DOB>
        <OrderingMD>Yeh, Yi-Chen</OrderingMD>
        <OrderingMDId>109266</OrderingMDId>
        <Pathologist>Not Provided</Pathologist>
        <CopiedPhysician1 />
        <MedFacilName>Taipei Veterans General Hospital</MedFacilName>
        <MedFacilID>205872</MedFacilID>
        <SpecSite>Lymph Node</SpecSite>
        <CollDate>2023-05-31</CollDate>
        <ReceivedDate>2023-06-09</ReceivedDate>
        <CountryOfOrigin>TW</CountryOfOrigin>
      </PMI>
      <PertinentNegatives>
        <PertinentNegative>
          <Gene>BRAF</Gene>
        </PertinentNegative>
        <PertinentNegative>
          <Gene>KIT</Gene>
        </PertinentNegative>
      </PertinentNegatives>
      <Summaries alterationCount="17" clinicalTrialCount="10" resistiveCount="0" sensitizingCount="3" />
      <VariantProperties>
        <VariantProperty geneName="ALK" isVUS="true" variantName="A1274T" />
        <VariantProperty geneName="DNMT3A" isVUS="true" variantName="S337L" />
        <VariantProperty geneName="KDM5A" isVUS="true" variantName="T269N" />
        <VariantProperty geneName="LTK" isVUS="true" variantName="G213_A214insGGG" />
        <VariantProperty geneName="PARP1" isVUS="true" variantName="A625T" />
        <VariantProperty geneName="PIK3C2G" isVUS="true" variantName="E88G,R981C" />
        <VariantProperty geneName="SNCAIP" isVUS="true" variantName="D451N" />
        <VariantProperty geneName="SPEN" isVUS="true" variantName="A2800V" />
      </VariantProperties>
      <priorTests />
      <Genes>
        <Gene>
          <Name>NRAS</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>Q61R</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="16.4" isEquivocal="false" name="Q61R" />
              </AlterationProperties>
              <Interpretation>NRAS encodes a member of the RAS family of small GTPases that mediate transduction of growth signals. Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF-MAPK-ERK, PI3K, and other pathways (Pylayeva-Gupta et al., 2011; 21993244). NRAS alterations affecting amino acids G12, G13, G60, Q61, as well as mutations I24N, T50I, T58I, and A146T have been characterized as activating and oncogenic (Buhrman et al., 2010; 20194776, Cirstea et al., 2010; 19966803, Colicelli, 2004; 15367757, Edkins et al., 2006; 16969076, Feig and Cooper, 1988; 3043178, Janakiraman et al., 2010; 20570890, Lukman et al., 2010; 20838576, Prior et al., 2012; 22589270, Privé et al., 1992; 1565661, Pylayeva-Gupta et al., 2011; 21993244, Runtuwene et al., 2011; 21263000, Scheffzek et al., 1997; 9219684, Smith et al., 2010; 20147967, Tyner et al., 2009; 19075190, Gremer et al., 2011; 20949621, Altmuller et al., 2017; 28594414, Hiippala et al., 2016; 26888048). NRAS mutations have been reported in ~20% of melanoma cases (7-33% in various studies), with similar frequency in primary and metastatic samples (Lee et al., 2011; 21166657, Xia et al., 2014; 24755198, Puig-Butillé et al., 2013; 23362874, Smalley, 2010; 19571822, Pylayeva-Gupta et al., 2011; 21993244, Monzon and Dancey, 2012; 22419879, Platz et al., 2008; 19383313, Omholt et al., 2002; 12429636, Ekedahl et al., 2013; 23855428, Dutton-Regester et al., 2013; 23890154). Similar frequencies of NRAS mutations have been reported in cutaneous melanoma, mucosal melanoma, acral lentiginous melanoma (ALM), conjunctival melanoma, vulvar melanoma, vaginal melanoma and melanoma of unknown primary (Lee et al., 2011; 21166657, Xia et al., 2014; 24755198, Jacob et al., 2012; 22180178, Zebary et al., 2013; 23993026, Griewank et al., 2013; 23633454, Uhara et al., 2014; 23739925, Wong et al., 2005; 15917418, Aulmann et al., 2014; 24603591, Wang et al., 2019; 31578274). Conflicting findings have been reported regarding the prognostic significance of NRAS mutation in the context of melanoma, with some studies noting significant adverse impact on clinico-pathological features as well as overall and/or melanoma-free survival (Jacob et al., 2012; 22180178, Devitt et al., 2011; 21615881, Birkland et al., 2013; 23673558, Mann et al., 2013; 22931913, Si et al., 2012; 21788131, Wang et al., 2019; 31578274), whereas other studies reported no significant impact on survival (Rutkowski et al., 2014; 24959217, Carlino et al., 2014; 24918823, Ekedahl et al., 2013; 23855428, Eqberts et al., 2014;24276025, Wu et al., 2014; 25048604, Griewank et al., 2013; 23633454). On the basis of clinical evidence in hematologic malignancies (Slosberg et al., 2018; 29765547, Ravandi et al., 2015; 26657199, Maiti et al., 2019; 30635233, Khanna et al., 2015; 26870618, Heuck et al., 2016; 26228812, Abdel-Wahab et al., 2014; 24589925, Holkova et al., 2016; 26446942) and solid tumors (Slosberg et al., 2018; 29765547, Wu et al., 2018; WCLC Abstract P1.01-97, Dummer et al., 2017; 28284557, Ascierto et al., 2013; 23414587, van Herpen et al., 2019; 30956763, van Herpen et al., 2014; 30956763), NRAS activating alterations may predict sensitivity to MEK inhibitors, such as trametinib, cobimetinib, binimetinib, and selumetinib. A Phase 3 study of the MEK inhibitor binimetinib in patients with NRAS-mutated melanoma who were previously untreated or had progressed on immunotherapy reported a significant increase in median progression-free survival as compared to dacarbazine (2.8 vs. 1.5 months) (Dummer et al., 2017; 28284557). In a nonrandomized Phase 2 study of binimetinib in 30 patients with NRAS-mutated melanoma, 20% (6/30) had a PR and 63% (19/30) had an SD, and the size of brain metastases was reduced in 2 patients treated with binimetinib (Ascierto et al., 2013; 23414587). A Phase 1 study of the ERK1/2 inhibitor ulixertinib reported PRs in 18% (3/17) and SDs in 35% (6/17) of patients with NRAS-mutated melanoma (Sullivan et al., 2018; 29247021). In a Phase 1 study, patients with NRAS-mutated melanoma benefited from treatment with belvarafenib, a type-II RAF inhibitor, with PRs reported in the dose-escalation (44% [4/9]) and dose-expansion (20% [2/10]) cohorts (Yen et al., 2021; 33953400). Retrospective analysis of patients with melanoma treated with first-line nivolumab plus ipilimumab showed significantly improved survival for those with BRAF-mutated disease (9.9 months median PFS [mPFS] and median OS [mOS] not reached) relative to those with either NRAS-mutated disease (4.8 months mPFS and 14.2 months mOS) or disease lacking BRAF and NRAS mutations (5.3 months mPFS and 16.1 months mOS) (van Not et al., 2022; 36130145). In a Phase 1 study evaluating the MEK-pan-RAF dual inhibitor CH5126766, 1 patient harboring an NRAS mutation experienced a PR (Martinez-Garcia et al., 2012; 22761467).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF-MAPK-ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.</ClinicalTrialNote>
              <Therapies>
                <Therapy>
                  <Name />
                  <GenericName>Cobimetinib</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Cobimetinib is a MEK inhibitor that is FDA approved to treat patients with histiocytic neoplasms. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of clinical evidence, activating alterations of NRAS may predict sensitivity to MEK inhibitors (Abdel-Wahab et al., 2014; 24589925, Ascierto et al., 2013; 23414587, Zimmer et al., 2014; 24947927, van Herpen et al., 2019; 30956763, Van Herpen et al., 2014; ESMO Abstract LBA35, Dummer et al., 2017; 28284557, Slosberg et al., 2018; 29765547, Khanna et al., 2015; 26870618, Goldinger et al., 2019; 31436845, Ravandi et al., 2015; 26657199). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; Significant clinical responses to various other MEK inhibitors have been documented in NRAS-mutant melanoma (Ascierto et al., 2013; 23414587, Adjei et al., 2008; 18390968, Zimmer et al., 2014; 24947927, Martinez-Garcia et al., 2012; 22761467). Patients with metastatic melanoma and NRAS mutations experienced PRs (26% [5/19]) and SDs (42% [8/19]) in response to cobimetinib combined with the RAF inhibitor belvarafenib (Kim et al., 2021; ESMO Abstract 529P). A Phase 1 study of cobimetinib monotherapy in solid tumors reported 1% (1/97) CR and 6% (6/97) PR, all of which were achieved by patients with melanoma (6 with BRAF V600E) (Rosen et al., 2016; 27424159). Patients with metastatic melanoma treated with cobimetinib combined with the RAF inhibitor belvarafenib experienced PRs for those with BRAF V600 mutations (33% [3/9]) and non-V600 mutations (50% [3/6])(Kim et al., 2021; ESMO Abstract 529P). In the Phase 3 IMspire170 study, the combination of atezolizumab and cobimetinib did not improve median PFS (5.5 vs. 5.7 months), ORR (26% vs. 32%) or 6-month OS (88% vs. 87%) compared with pembrolizumab for patients with previously untreated BRAF V600 wildtype melanoma (Arance et al., 2019; ESMO Abstract LBA69). Similarly, the Phase 2 TRICOTEL trial for patients with BRAF wildtype melanoma with central nervous system metastases reported an intracranial ORR of 27% following combination treatment of atezolizumab and cobimetinib (Dummer et al., 2022; 35940183). A Phase 1b study evaluating the combination of atezolizumab and cobimetinib for the treatment of patients with solid tumors reported an ORR of 41% (9/22) in patients with melanoma, regardless of BRAF status; the 12-month PFS and OS rates were 50% and 85%, respectively (Hellman et al., 2019; 30918950). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Selumetinib</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Selumetinib is a MEK inhibitor that is FDA approved to treat pediatric patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PNs). Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of clinical evidence, activating alterations of NRAS may predict sensitivity to MEK inhibitors (Abdel-Wahab et al., 2014; 24589925, Ascierto et al., 2013; 23414587, Zimmer et al., 2014; 24947927, van Herpen et al., 2019; 30956763, Van Herpen et al., 2014; ESMO Abstract LBA35, Dummer et al., 2017; 28284557, Slosberg et al., 2018; 29765547, Khanna et al., 2015; 26870618, Goldinger et al., 2019; 31436845, Ravandi et al., 2015; 26657199). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; In a Phase 2 study for patients with metastatic melanoma, selumetinib monotherapy achieved an ORR of 5.8%; among patients with BRAF mutations, the ORR was 11% (5/45) (Kirkwood et al., 2012; 22048237). In a Phase 2 trial of first-line treatment of BRAF-mutated metastatic melanoma, the addition of selumetinib to dacarbazine increased PFS compared to dacarbazine plus placebo (5.6 vs 3.0 months, HR=0.63) but did not significantly improve OS (13.9 vs 10.5 months, HR 0.93, p=0.39) (Robert et al., 2013; 23735514). In a Phase 2 trial for patients with BRAF wildtype advanced melanoma, the addition of selumetinib to docetaxel did not improve median PFS compared to docetaxel plus placebo (4.2 vs 3.9 months) and was associated with lower OS (9.5 months vs 11.4 months); NRAS mutation was associated with inferior OS (HR=0.78) (Gupta et al., 2014; 24567366). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Trametinib</GenericName>
                  <FDAApproved>true</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Trametinib is a MEK inhibitor that is FDA approved as a monotherapy to treat patients with melanoma with BRAF V600E or V600K mutations. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of clinical evidence, activating alterations of NRAS may predict sensitivity to MEK inhibitors (Abdel-Wahab et al., 2014; 24589925, Ascierto et al., 2013; 23414587, Zimmer et al., 2014; 24947927, van Herpen et al., 2019; 30956763, Van Herpen et al., 2014; ESMO Abstract LBA35, Dummer et al., 2017; 28284557, Slosberg et al., 2018; 29765547, Khanna et al., 2015; 26870618, Goldinger et al., 2019; 31436845, Ravandi et al., 2015; 26657199). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; One retrospective study of MEK inhibitors in NRAS-mutated melanoma reported an ORR of 23% (5/22) for pretreated patients with trametinib as a single agent (Salzmann et al., 2022; 35272084), although efficacy was limited in a Phase 1 trial of advanced melanoma (0 PRs, 29% DCR [2/7]) (Falchook et al., 2012; 22805292). A real-world study of trametinib with or without anti-PD1 antibodies in immune checkpoint inhibitor (ICI)-resistant melanoma reported PRs for 5% (1/20) of patients with NRAS-mutated disease and a median OS of 6.5 months for the cohort overall (n=22) (Pigne et al., 2023; 36919691). The combination of trametinib with paclitaxel resulted in PRs for 50% (4/8) of patients with melanoma harboring NRAS mutations (Coupe et al., 2015; 25542057). Combination approaches pairing trametinib with other agents are also under investigation in NRAS-mutated melanoma. A Phase 2 study of trametinib and the BRAF/CRAF inhibitor LXH254 reported 1 PR and a DCR of 67% (16/24) for patients with ICI-resistant disease at the expansion dose (Lebbe et al., 2022; ESMO Abstract LBA40), building on a Phase 1b trial reporting an ORR of 47% (7/15) (de Braud et al., 2022; AACR Abstract CT197). A study reported responses for 25% (1/4) of patients with the combination of trametinib and ICIs (Salzmann et al., 2022; 35272084). As a monotherapy for patients with BRAF V600E/K-mutated metastatic melanoma, trametinib improved PFS (4.9 vs. 1.5 months, HR=0.54) and median OS (15.6 vs. 11.3 months, HR=0.84) compared with patients treated with chemotherapy (Robert et al., 2019; 30690294). In a Phase 1 study, 10% (4/40) of patients with BRAF-wildtype metastatic melanoma achieved a PR (Falchook et al., 2012; 22805292). Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated &gt;3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
              </Therapies>
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT04913285">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04803318">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04985604">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04835805">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03284502">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05580770">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04551521">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04892017">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05340621">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04720976">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>MUTYH</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>splice site 892-2A&gt;G</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="39.8" isEquivocal="false" name="splice site 892-2A&gt;G" />
              </AlterationProperties>
              <Interpretation>MUTYH (also known as MYH) encodes an enzyme involved in DNA base excision repair, and loss of function mutations in MUTYH result in increased rates of mutagenesis and promotion of tumorigenesis (David et al., 2007; 17581577). The two most frequently reported MUTYH loss of function mutations are G382D (also referred to as G396D) and Y165C (also referred to as Y179C) (Molatore et al., 2010; 19953527, Kundu et al., 2009; 19836313, D'Agostino et al., 2010; 20418187, Hegde et al., 2014; 24310308, Aretz et al., 2013; 22872101). Numerous other MUTYH mutations have also been shown to result in loss of function (Molatore et al., 2010; 19953527, Kundu et al., 2009; 19836313, Ali et al., 2008; 18534194, D'Agostino et al., 2010; 20418187). In general, somatic MUTYH mutations are infrequently reported across cancer types (COSMIC, 2023)(Tate et al., 2019; 30371878). Monoallelic MUTYH mutation occurs in 1-2% of the general population (Hegde et al., 2014; 24310308, Aretz et al., 2013; 22872101). There are conflicting data regarding the impact of monoallelic mutations on the risk of developing colorectal cancer (CRC) (Win et al., 2014; 24444654, Lubbe et al., 2009; 19620482, Jones et al., 2009; 19394335). Patients with MUTYH-mutated CRC were reported to have significantly improved OS compared with patients without MUTYH mutation (Nielsen et al., 2010; 21044966). There are no therapies or clinical trials available to address MUTYH alterations in cancer. One or more of the MUTYH variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with MUTYH-associated polyposis (ClinVar, Apr 2023)(Landrum et al., 2018; 29165669). Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline biallelic MUTYH mutation causes MUTYH-associated polyposis (also known as MYH-associated polyposis or MAP), an autosomal recessive condition characterized by multiple colorectal adenomas and increased lifetime risk of colorectal cancer (CRC) (Hegde et al., 2014; 24310308, Sampson et al., 2003; 12853198, Sieber et al., 2003; 12606733, Al-Tassan et al., 2002; 11818965). MAP accounts for approximately 0.7% of all CRC cases and 2% of early-onset CRC cases (Hegde et al., 2014; 24310308). In contrast to CRC, the role of MUTYH mutation in the context of other cancer types is not well established (Rennert et al., 2012; 21952991, Zhang et al., 2006; 16492928, von der Thüsen et al., 2011; 21189386, Casper et al., 2014; 24420788, Smith et al., 2009; 20110747). Estimates for the prevalence of MAP in the general population range from 1:5,000-1:10,000 (Aretz et al., 2013; 22872101). Therefore, in the appropriate clinical context, germline testing of MUTYH is recommended.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>Microsatellite status</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>MS-Stable</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="MS-Stable" />
              </AlterationProperties>
              <Interpretation>Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI has been detected in 16-32% of cutaneous melanomas in several small datasets, with the majority exhibiting MSI-low (Kubecek et al., 2016; 27623135). A higher frequency of MSI (low and high) has been reported in metastatic tumors (20-77%) compared to primary tumors (2-30%) (Kubecek et al., 2016; 27372860). No association between MSI status and clinicopathological features of patients with melanoma was reported in one study (Peris et al., 1995; 7561170). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO-SITC Abstract P60).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>PRDM1</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>V10fs*10</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="52.48" isEquivocal="false" name="V10fs*10" />
              </AlterationProperties>
              <Interpretation>PRDM1 encodes the transcriptional repressor protein BLIMP-1, which antagonizes expression of beta-interferon, among other genes (Keller and Maniatis, 1991; 1851123). BLIMP-1 plays a key role in mediating terminal differentiation of myeloid cells and B-lymphocytes, in part through repression of c-MYC transcription (Chang et al., 2000; 11248811). Inactivating somatic alterations of PRDM1 have been shown to occur in approximately one quarter of activated B-cell type diffuse large B-cell lymphomas (ABC-DLBCL) but not in other DLBCL subtypes (Pasqualucci et al., 2006; 16492805). In contrast to this tumor suppressor role in lymphoma, BLIMP-1 activity has been hypothesized to promote cell migration and invasion based on cell culture models of lung cancer (Yu et al., 2012; 22438909). There are no targeted therapies available to address genomic alterations in PRDM1.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>SGK1</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>loss exons 1-12</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="loss exons 1-12" />
              </AlterationProperties>
              <Interpretation>SGK1 encodes serum/glucocorticoid regulated kinase 1, which activates ion channels in response to cellular stress. SGK1 can be activated by PI3K-mTORC2 signaling (García-Martínez et al., 2008; 18925875) and can in turn activate mTORC1 (Castel et al., 2016; 27451907). SGK1 mutation has been observed in 6-16% of diffuse large B-cell lymphomas (cBio-Lohr et al., 2012; 22343534), 5/7 cases of variant nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), and 1/6 cases of typical NLPHL (Hartmann et al., 2016; 26658840). SGK1 amplification and mutation have rarely been observed in other tumor types (cBioPortal, COSMIC, 2023)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878). Increased SGK1 expression has been reported in lung squamous cell carcinoma (Abbruzzese et al., 2012; 22240294), endometrioid endometrial carcinoma (Conza et al., 2017; 28177128), glioblastoma (Talarico et al., 2016; 26908461), and breast cancer (Sahoo et al., 2005; 16246546). The PI3K inhibitor LY294002 has been reported to block SGK1 activity in a preclinical study (Park et al., 1999; 10357815). Several SGK1 inhibitors (Ackermann et al., 2011; 21865856, Castel et al., 2016; 27451907, Halland et al., 2014; 25589934, Mansley et al., 2010; 20880397, O'Neill et al., 2015; 26267320, Sherk et al., 2008; 18794135) have been developed but are not suitable for clinical use. SGK1 and NDRG1 expression were reported to be increased in three PIK3CA-mutant breast cancer samples from patients who did not respond to treatment with the PI3K inhibitor BYL719 in combination with aromatase inhibitor (Castel et al., 2016; 27451907). Additionally, preclinical studies have reported that SGK1 expression confers resistance to BYL719 in breast cancer cells harboring PIK3CA activating mutations (Castel et al., 2016; 27451907) and to the AKT inhibitors AZD5363 and MK2206 in breast cancer cells (Sommer et al., 2013; 23581296).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>SMAD2</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>loss exons 7-8</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="loss exons 7-8" />
              </AlterationProperties>
              <Interpretation>SMAD2 encodes an intracellular transducer that is activated by TGF-beta or activin to dimerize with SMAD4 and regulate transcription of TGF-beta or activin-activated genes (Lebrun et al., 1999; 9892009, Lin et al., 2006; 16751101). SMAD2 alterations that disrupt the MH1 domain (amino acids 10-176), MH2 domain (amino acids 274-467), or critical phosphorylation sites are predicted to result in a loss of function (Fleming et al., 2013; 23139211, Funaba et al., 2002; 12193595, Macías-Silva et al., 1996; 8980228, Massague et al., 2005; 16322555, Matsuzaki et al., 2009; 19531654, Wu et al., 2012; 22539990). SMAD2 mutations have been reported in various tumor types, including cutaneous squamous cell carcinoma (SCC; 6-10%)(Li et al., 2015; 25589618), colorectal adenocarcinoma (CRC; 3-7%)(Fleming et al., 2013; 23139211, Cancer Genome Atlas Network., 2012; 22810696), endometrial cancers (2-5%)(Cancer Genome Atlas Research Network., 2013; 23636398), stomach adenocarcinoma (2-3%)(Cancer Genome Atlas Research Network., 2014; 25079317), lung SCC (1-2%)(Cancer Genome Atlas Research Network., 2012; 22960745), and lung adenocarcinoma (1-2%)(Cancer Genome Atlas Research Network., 2014; 25079552, cBio-Imielinski et al., 2012; 22980975, Uchida et al., 1996; 8971158, cBio-Ding et al., 2008; 18948947). SMAD2 deletion, as well as loss of expression or phosphorylation (p-SMAD2), has been reported in several cancers (Boulay et al., 2001; 11391794, Xie et al., 2003; 12967141, Koumoundourou et al., 2007; 17695423, Xie et al., 2002; 11809701, Liapis et al., 2007; 17295676, Wu et al., 2007; 17729405, Macías-Silva et al., 1996; 8980228) and has been correlated with poor prognosis in hepatocellular, gastric, breast, and colorectal cancer (Xie et al., 2003; 12967141, Koumoundourou et al., 2007; 17695423, Xie et al., 2002; 11809701, Liapis et al., 2007; 17295676, Wu et al., 2007; 17729405) but good prognosis in HNSCC (Xie et al., 2013; 22275186, Mangone et al., 2010; 20462450). There are no therapies that target the loss of SMAD2 or loss of TGF-beta signaling in cancer. Because TGF-beta can exert both tumor suppressor as well as pro-tumor effects, the development of therapies aimed at this pathway must be carefully considered for each patient. In preclinical studies, several novel small-molecule TGF-beta pathway inhibitors have been shown to reduce SMAD2 phosphorylation and tumor invasion in breast cancer cells and to increase survival in mouse xenograft models (Ehata et al., 2007; 17129361, Rausch et al., 2009; 19528470).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>TERT</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>promoter -146C&gt;T</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="17.28" isEquivocal="false" name="promoter -146C&gt;T" />
              </AlterationProperties>
              <Interpretation>Telomerase reverse transcriptase (TERT, or hTERT) is a catalytic subunit of the telomerase complex, which is required to maintain appropriate chromosomal length (Shay et al., 2011; 22015685). Activation of TERT is a hallmark of cancer, being detected in up to 80-90% of malignancies and absent in quiescent cells (Shay et al., 1997; 9282118, Kim et al., 1994; 7605428, Hanahan and Weinberg, 2000; 10647931). Mutations within the promoter region of TERT that confer enhanced TERT promoter activity have been reported in two hotspots, located at -124 bp and -146 bp upstream of the transcriptional start site (also termed C228T and C250T, respectively)(Horn et al., 2013; 23348503, Huang et al., 2014; 23348506, Vinagre et al., 2013; 23887589), as well as tandem mutations at positions –124/–125 bp and –138/–139 bp (Horn et al., 2013; 23348503). TERT promoter mutations have been reported in 22-71% of melanoma cases, including 85% of metastatic melanomas, 66% of unknown primary melanomas, 32% (12/38) of conjunctival melanomas, 13.2% (7/53) of mucosal melanomas, 6% (2/32) of acral lentiginous melanomas, and 1/50 uveal melanomas (Populo et al., 2014; 24691053, Eqberts et al., 2014; 24463461, Huang et al., 2013; 23348506, Horn et al., 2013; 23348503, Liau et al., 2014; 24588324, Scott et al., 2014; 24030752, Griewank et al., 2013; 23799844, Vinagre et al., 2013; 23887589). TERT promoter mutations associate with increased TERT expression in melanoma (Heidenreich et al., 2014; 24569790, Huang et al., 2013; 23348506, Horn et al., 2013; 23348503). Gains of the TERT locus have also been reported in 31.2% (5/16) of melanomas (Puig-Butille et al., 2013; 23362874). TERT promoter mutations or protein overexpression has been associated with poor clinico-pathological features, but not with impact on survival (Populo et al., 2014; 24691053, Eqberts et al., 2014; 24463461, Heidenreich et al., 2014; 24569790, Zygouris et al., 2007; 18067210). In addition, germline polymorphisms in TERT have been associated with risk of melanoma development (Law et al., 2012; 21993562, Yin et al., 2012; 23226346, Nan et al., 2011; 21116649). Therapeutic options for targeting tumors with TERT mutations are limited, although a variety of approaches have been investigated, including immunotherapies using TERT as a tumor-associated antigen and antisense oligonucleotide- or peptide-based therapies. TERT peptide vaccines showed limited anticancer efficacy in clinical trials (Zanetti et al., 2017; 27245281); however, in one preclinical study, the combination of a TERT peptide vaccine and anti-CTLA-4 therapy suppressed tumor growth (Duperret at al., 2018; 29249395). A Phase 2 study of the TERT inhibitor imetelstat for patients with advanced non-small cell lung cancer reported no improvement in PFS or OS (Chiappori et al., 2015; 25467017).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>Tumor Mutation Burden</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>01</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="01" />
              </AlterationProperties>
              <Interpretation>Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide-based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents (Johnson et al., 2016; 27671167, Goodman et al., 2017; 28835386, Eroglu et al, 2018; 29320474, Shin et al., 2017; 27903500, Riaz et al., 2017; 29033130, Cristescu et al., 2018; 30309915, Samstein et al., 2019; 30643254, Ribas et al., 2019; AACR abstract 4217, Hodi et al., 2019; AACR abstract CT037, Marabelle et al., 2020; 32919529). A large-scale genomic analysis found that various melanoma subtypes harbored median TMBs between 6.3 and 14.4 Muts/Mb, and 25% to 40% of cases had elevated TMBs of greater than 20 Muts/Mb (FMI-Chalmers et al., 2017; 28420421). Malignant melanoma has been reported to have a high prevalence of somatic mutations compared with other tumor types (Alexandrov et al., 2013; 23945592), with desmoplastic melanoma ranking among the highest of melanoma subtypes (median TMB of 62 Muts/Mb)(Shain et al., 2015; 26343386). Higher mutational load has been reported in NF1-mutant melanoma samples compared with BRAF-mutant, NRAS-mutant, or BRAF/NRAS/NF1 wild-type samples (Johnson et al., 2016; 27671167). In 1 study, elevated TMB correlated with PD-L1 positive status and increased OS in tissue specimens from patients with Stage 3 melanoma (Madore et al., 2016; 26960397). In another study, elevated tissue TMB (&gt;20 Muts/Mb) was associated with longer PFS and OS in patients treated with anti-PD-1 or anti-PD-L1 immunotherapy as compared with patients with lower TMB (Johnson et al., 2016; 27671167). Increased TMB has also been associated with histologic stage and cumulative sun exposure (Shain et al., 2015; 26559571). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti-PD-1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple studies of immune checkpoint inhibitors in melanoma, higher TMB has corresponded with clinical benefit from treatment with anti-PD-1 or anti-PD-L1 treatments (Hodi et al., 2019; AACR Abstract CT037, Ribas et al., 2019; AACR Abstract 4217, Cristescu et al., 2018; 30309915, Johnson et al., 2016; 27671167, Ning et al., 2022; 35355708). Increased TMB has been associated with longer PFS and OS for patients with melanoma treated with nivolumab, with studies reporting increased benefit for patients with a mutational load above 162 missense mutations per tumor (~equivalency &gt;8 Muts/Mb as measured by this assay) (Hodi et al., 2019; AACR abstract CT037). Increased TMB (~equivalency &gt;10.8 Muts/Mb as measured by this assay) has also been associated with longer PFS and OS for patients with melanoma treated with combination nivolumab and ipilumumab (Hodi et al., 2019; AACR abstract CT037). Improved PFS and OS of patients with melanoma treated with ipilumumab has been observed across all TMB levels (Ribas et al., 2019; AACR abstract 4217, Liu et al., 2019; 31515453).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
      </Genes>
      <Trials>
        <Trial>
          <Gene>NRAS</Gene>
          <Alteration>Q61R</Alteration>
          <Title>A Study to Evaluate KIN-2787 in Subjects With BRAF Mutation Positive Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>BRAF, MEK</Target>
          <Locations>Taipei (Taiwan), Shanghai (China), Bengbu (China), Wuhan (China), Linyi (China), Gyeonggi-do (Korea, Republic of), Cheongju-si (Korea, Republic of), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Beijing (China)</Locations>
          <NCTID>NCT04913285</NCTID>
          <Note>Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF-MAPK-ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>NRAS</Gene>
          <Alteration>Q61R</Alteration>
          <Title>Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK</Target>
          <Locations>Guangzhou (China)</Locations>
          <NCTID>NCT04803318</NCTID>
          <Note>Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF-MAPK-ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>NRAS</Gene>
          <Alteration>Q61R</Alteration>
          <Title>DAY101 Monotherapy or in Combination With Other Therapies for Patients With Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>BRAF, MEK</Target>
          <Locations>Busan (Korea, Republic of), Seoul (Korea, Republic of), Clayton (Australia), Edegem (Belgium), Oregon, Barcelona (Spain), Madrid (Spain), California, Colorado</Locations>
          <NCTID>NCT04985604</NCTID>
          <Note>Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF-MAPK-ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>NRAS</Gene>
          <Alteration>Q61R</Alteration>
          <Title>A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Atezolizumab in Patients With NRAS-mutant Advanced Melanoma.</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>MEK, RAFs, NRAS, PD-L1</Target>
          <Locations>Seoul (Korea, Republic of), Nedlands (Australia), Waratah (Australia), Melbourne (Australia), Oslo (Norway), Bergen (Norway), Berlin (Germany), Hamburg (Germany), Würzburg (Germany), Mannheim (Germany)</Locations>
          <NCTID>NCT04835805</NCTID>
          <Note>Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF-MAPK-ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>NRAS</Gene>
          <Alteration>Q61R</Alteration>
          <Title>Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>MEK, RAFs, NRAS</Target>
          <Locations>Hwasun (Korea, Republic of), Pusan (Korea, Republic of), Seongnam (Korea, Republic of), Seoul (Korea, Republic of), Goyang-si (Korea, Republic of)</Locations>
          <NCTID>NCT03284502</NCTID>
          <Note>Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF-MAPK-ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>NRAS</Gene>
          <Alteration>Q61R</Alteration>
          <Title>Mirdametinib + BGB-3245 in Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>BRAF, MEK</Target>
          <Locations>Waratah (Australia), Melbourne (Australia), California, Ohio, Massachusetts, Texas, Connecticut, Florida</Locations>
          <NCTID>NCT05580770</NCTID>
          <Note>Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF-MAPK-ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>NRAS</Gene>
          <Alteration>Q61R</Alteration>
          <Title>CRAFT: The NCT-PMO-1602 Phase II Trial</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>PD-L1, AKTs, MEK, BRAF, ALK, RET, ERBB2</Target>
          <Locations>Lübeck (Germany), Würzburg (Germany), Mainz (Germany), Heidelberg (Germany), Tübingen (Germany)</Locations>
          <NCTID>NCT04551521</NCTID>
          <Note>Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF-MAPK-ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>NRAS</Gene>
          <Alteration>Q61R</Alteration>
          <Title>A Safety, Tolerability and PK Study of DCC-3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors.</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>ULK1, ULK2, MEK</Target>
          <Locations>Oregon, Massachusetts, New York, Texas, Pennsylvania</Locations>
          <NCTID>NCT04892017</NCTID>
          <Note>Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF-MAPK-ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>NRAS</Gene>
          <Alteration>Q61R</Alteration>
          <Title>OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>HDACs, MEK</Target>
          <Locations>California, Michigan, Massachusetts, New York, Tennessee, Virginia, Texas, Georgia, Florida</Locations>
          <NCTID>NCT05340621</NCTID>
          <Note>Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF-MAPK-ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>NRAS</Gene>
          <Alteration>Q61R</Alteration>
          <Title>JAB-3312 Activity in Adult Patients With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>MEK, SHP2, PD-1, EGFR, KRAS</Target>
          <Locations>Utah, California, Arizona, Minnesota, Illinois, Michigan, Oklahoma, Missouri, Indiana, Connecticut</Locations>
          <NCTID>NCT04720976</NCTID>
          <Note>Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF-MAPK-ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.</Note>
          <Include>true</Include>
        </Trial>
      </Trials>
      <References>
        <Reference number="0">
          <ReferenceId>21993244</ReferenceId>
          <FullCitation>Pylayeva-Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="1">
          <ReferenceId>20194776</ReferenceId>
          <FullCitation>Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20194776</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="2">
          <ReferenceId>19966803</ReferenceId>
          <FullCitation>Cirstea IC, et al. Nat. Genet. (2010) pmid: 19966803</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="3">
          <ReferenceId>15367757</ReferenceId>
          <FullCitation>Sci. STKE (2004) pmid: 15367757</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="4">
          <ReferenceId>16969076</ReferenceId>
          <FullCitation>Edkins S, et al. Cancer Biol. Ther. (2006) pmid: 16969076</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="5">
          <ReferenceId>3043178</ReferenceId>
          <FullCitation>Feig LA, et al. Mol. Cell. Biol. (1988) pmid: 3043178</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="6">
          <ReferenceId>20570890</ReferenceId>
          <FullCitation>Janakiraman M, et al. Cancer Res. (2010) pmid: 20570890</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="7">
          <ReferenceId>20838576</ReferenceId>
          <FullCitation>Lukman S, et al. PLoS Comput. Biol. (2010) pmid: 20838576</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="8">
          <ReferenceId>22589270</ReferenceId>
          <FullCitation>Prior IA, et al. Cancer Res. (2012) pmid: 22589270</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="9">
          <ReferenceId>1565661</ReferenceId>
          <FullCitation>Privé GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) pmid: 1565661</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="10">
          <ReferenceId>21263000</ReferenceId>
          <FullCitation>Runtuwene V, et al. Dis Model Mech (2011) pmid: 21263000</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="11">
          <ReferenceId>9219684</ReferenceId>
          <FullCitation>Scheffzek K, et al. Science (1997) pmid: 9219684</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="12">
          <ReferenceId>20147967</ReferenceId>
          <FullCitation>Smith G, et al. Br. J. Cancer (2010) pmid: 20147967</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="13">
          <ReferenceId>19075190</ReferenceId>
          <FullCitation>Tyner JW, et al. Blood (2009) pmid: 19075190</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="14">
          <ReferenceId>20949621</ReferenceId>
          <FullCitation>Gremer L, et al. Hum. Mutat. (2011) pmid: 20949621</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="15">
          <ReferenceId>28594414</ReferenceId>
          <FullCitation>Altmüller F, et al. Eur J Hum Genet (2017) pmid: 28594414</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="16">
          <ReferenceId>26888048</ReferenceId>
          <FullCitation>Hiippala A, et al. Am. J. Med. Genet. A (2016) pmid: 26888048</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="17">
          <ReferenceId>21166657</ReferenceId>
          <FullCitation>Lee JH, et al. Br. J. Dermatol. (2011) pmid: 21166657</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="18">
          <ReferenceId>24755198</ReferenceId>
          <FullCitation>Xia J, et al. Mol. Cancer Ther. (2014) pmid: 24755198</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="19">
          <ReferenceId>23362874</ReferenceId>
          <FullCitation>Puig-Butillé JA, et al. Exp. Dermatol. (2013) pmid: 23362874</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="20">
          <ReferenceId>19571822</ReferenceId>
          <FullCitation>J. Invest. Dermatol. (2010) pmid: 19571822</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="21">
          <ReferenceId>22419879</ReferenceId>
          <FullCitation>Monzon JG, et al. Onco Targets Ther (2012) pmid: 22419879</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="22">
          <ReferenceId>19383313</ReferenceId>
          <FullCitation>Platz A, et al. Mol Oncol (2008) pmid: 19383313</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="23">
          <ReferenceId>12429636</ReferenceId>
          <FullCitation>Omholt K, et al. Clin. Cancer Res. (2002) pmid: 12429636</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="24">
          <ReferenceId>23855428</ReferenceId>
          <FullCitation>Ekedahl H, et al. Br. J. Dermatol. (2013) pmid: 23855428</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="25">
          <ReferenceId>23890154</ReferenceId>
          <FullCitation>Dutton-Regester K, et al. Pigment Cell Melanoma Res (2013) pmid: 23890154</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="26">
          <ReferenceId>22180178</ReferenceId>
          <FullCitation>Jakob JA, et al. Cancer (2012) pmid: 22180178</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="27">
          <ReferenceId>23993026</ReferenceId>
          <FullCitation>Zebary A, et al. J. Dermatol. Sci. (2013) pmid: 23993026</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="28">
          <ReferenceId>23633454</ReferenceId>
          <FullCitation>Griewank KG, et al. Clin. Cancer Res. (2013) pmid: 23633454</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="29">
          <ReferenceId>23739925</ReferenceId>
          <FullCitation>Uhara H, et al. Int. J. Clin. Oncol. (2014) pmid: 23739925</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="30">
          <ReferenceId>15917418</ReferenceId>
          <FullCitation>Wong CW, et al. J. Clin. Pathol. (2005) pmid: 15917418</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="31">
          <ReferenceId>24603591</ReferenceId>
          <FullCitation>Aulmann S, et al. Mod. Pathol. (2014) pmid: 24603591</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="32">
          <ReferenceId>31578274</ReferenceId>
          <FullCitation>Wang HY, et al. Oncologist (2019) pmid: 31578274</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="33">
          <ReferenceId>21615881</ReferenceId>
          <FullCitation>Devitt B, et al. Pigment Cell Melanoma Res (2011) pmid: 21615881</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="34">
          <ReferenceId>23673558</ReferenceId>
          <FullCitation>Birkeland E, et al. Clin. Exp. Metastasis (2013) pmid: 23673558</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="35">
          <ReferenceId>22931913</ReferenceId>
          <FullCitation>Mann GJ, et al. J. Invest. Dermatol. (2013) pmid: 22931913</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="36">
          <ReferenceId>21788131</ReferenceId>
          <FullCitation>Si L, et al. Eur. J. Cancer (2012) pmid: 21788131</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="37">
          <ReferenceId>24959217</ReferenceId>
          <FullCitation>Rutkowski P, et al. Oncol Lett (2014) pmid: 24959217</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="38">
          <ReferenceId>24918823</ReferenceId>
          <FullCitation>Carlino MS, et al. Br. J. Cancer (2014) pmid: 24918823</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="39">
          <ReferenceId>24276025</ReferenceId>
          <FullCitation>Egberts F, et al. Ann. Oncol. (2014) pmid: 24276025</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="40">
          <ReferenceId>25048604</ReferenceId>
          <FullCitation>Wu S, et al. Cancer Causes Control (2014) pmid: 25048604</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="41">
          <ReferenceId>29765547</ReferenceId>
          <FullCitation>Slosberg ED, et al. Oncotarget (2018) pmid: 29765547</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="42">
          <ReferenceId>26657199</ReferenceId>
          <FullCitation>Ravandi F, et al. Blood Cancer J (2015) pmid: 26657199</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="43">
          <ReferenceId>30635233</ReferenceId>
          <FullCitation>Maiti A, et al. Clin Lymphoma Myeloma Leuk (2019) pmid: 30635233</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="44">
          <ReferenceId>26870618</ReferenceId>
          <FullCitation>Khanna V, et al. Cureus (2015) pmid: 26870618</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="45">
          <ReferenceId>26228812</ReferenceId>
          <FullCitation>Heuck CJ, et al. Leukemia (2016) pmid: 26228812</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="46">
          <ReferenceId>24589925</ReferenceId>
          <FullCitation>Abdel-Wahab O, et al. Cancer Discov (2014) pmid: 24589925</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="47">
          <ReferenceId>26446942</ReferenceId>
          <FullCitation>Holkova B, et al. Clin. Cancer Res. (2016) pmid: 26446942</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="48">
          <ReferenceId>28284557</ReferenceId>
          <FullCitation>Dummer R, et al. Lancet Oncol. (2017) pmid: 28284557</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="49">
          <ReferenceId>23414587</ReferenceId>
          <FullCitation>Ascierto PA, et al. Lancet Oncol. (2013) pmid: 23414587</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="50">
          <ReferenceId>30956763</ReferenceId>
          <FullCitation>van Herpen CML, et al. Oncotarget (2019) pmid: 30956763</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="51">
          <ReferenceId>29247021</ReferenceId>
          <FullCitation>Sullivan RJ, et al. Cancer Discov (2018) pmid: 29247021</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="52">
          <ReferenceId>33953400</ReferenceId>
          <FullCitation>Yen I, et al. Nature (2021) pmid: 33953400</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="53">
          <ReferenceId>36130145</ReferenceId>
          <FullCitation>van Not OJ, et al. JCO Precis Oncol (2022) pmid: 36130145</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="54">
          <ReferenceId>22761467</ReferenceId>
          <FullCitation>Martinez-Garcia M, et al. Clin. Cancer Res. (2012) pmid: 22761467</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="55">
          <ReferenceId>1851123</ReferenceId>
          <FullCitation>Keller AD, et al. Genes Dev. (1991) pmid: 1851123</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="56">
          <ReferenceId>11248811</ReferenceId>
          <FullCitation>Chang DH, et al. Nat. Immunol. (2000) pmid: 11248811</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="57">
          <ReferenceId>16492805</ReferenceId>
          <FullCitation>Pasqualucci L, et al. J. Exp. Med. (2006) pmid: 16492805</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="58">
          <ReferenceId>22438909</ReferenceId>
          <FullCitation>Yu Z, et al. PLoS ONE (2012) pmid: 22438909</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="59">
          <ReferenceId>26337942</ReferenceId>
          <FullCitation>Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="60">
          <ReferenceId>21081928</ReferenceId>
          <FullCitation>You JF, et al. Br. J. Cancer (2010) pmid: 21081928</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="61">
          <ReferenceId>24623249</ReferenceId>
          <FullCitation>Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="62">
          <ReferenceId>9823339</ReferenceId>
          <FullCitation>Boland CR, et al. Cancer Res. (1998) pmid: 9823339</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="63">
          <ReferenceId>15528785</ReferenceId>
          <FullCitation>Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="64">
          <ReferenceId>20420947</ReferenceId>
          <FullCitation>Boland CR, et al. Gastroenterology (2010) pmid: 20420947</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="65">
          <ReferenceId>27623135</ReferenceId>
          <FullCitation>Kubeček O, et al. Melanoma Res. (2016) pmid: 27623135</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="66">
          <ReferenceId>27372860</ReferenceId>
          <FullCitation>Kubecek O, et al. Med. Hypotheses (2016) pmid: 27372860</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="67">
          <ReferenceId>7561170</ReferenceId>
          <FullCitation>Peris K, et al. J. Invest. Dermatol. (1995) pmid: 7561170</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="68">
          <ReferenceId>25392179</ReferenceId>
          <FullCitation>Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="69">
          <ReferenceId>26140250</ReferenceId>
          <FullCitation>Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="70">
          <ReferenceId>25949894</ReferenceId>
          <FullCitation>Lal N, et al. Oncoimmunology (2015) pmid: 25949894</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="71">
          <ReferenceId>26028255</ReferenceId>
          <FullCitation>Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="72">
          <ReferenceId>18925875</ReferenceId>
          <FullCitation>García-Martínez JM, et al. Biochem. J. (2008) pmid: 18925875</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="73">
          <ReferenceId>27451907</ReferenceId>
          <FullCitation>Castel P, et al. Cancer Cell (2016) pmid: 27451907</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="74">
          <ReferenceId>22343534</ReferenceId>
          <FullCitation>Lohr JG, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22343534</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="75">
          <ReferenceId>26658840</ReferenceId>
          <FullCitation>Hartmann S, et al. Leukemia (2016) pmid: 26658840</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="76">
          <ReferenceId>22588877</ReferenceId>
          <FullCitation>Cerami E, et al. Cancer Discov (2012) pmid: 22588877</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="77">
          <ReferenceId>23550210</ReferenceId>
          <FullCitation>Gao J, et al. Sci Signal (2013) pmid: 23550210</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="78">
          <ReferenceId>30371878</ReferenceId>
          <FullCitation>Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="79">
          <ReferenceId>22240294</ReferenceId>
          <FullCitation>Abbruzzese C, et al. J. Exp. Clin. Cancer Res. (2012) pmid: 22240294</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="80">
          <ReferenceId>28177128</ReferenceId>
          <FullCitation>Conza D, et al. J. Cell. Physiol. (2017) pmid: 28177128</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="81">
          <ReferenceId>26908461</ReferenceId>
          <FullCitation>Talarico C, et al. Oncotarget (2016) pmid: 26908461</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="82">
          <ReferenceId>16246546</ReferenceId>
          <FullCitation>Sahoo S, et al. Eur. J. Cancer (2005) pmid: 16246546</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="83">
          <ReferenceId>10357815</ReferenceId>
          <FullCitation>Park J, et al. EMBO J. (1999) pmid: 10357815</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="84">
          <ReferenceId>21865856</ReferenceId>
          <FullCitation>Ackermann TF, et al. Cell. Physiol. Biochem. (2011) pmid: 21865856</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="85">
          <ReferenceId>25589934</ReferenceId>
          <FullCitation>Halland N, et al. ACS Med Chem Lett (2015) pmid: 25589934</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="86">
          <ReferenceId>20880397</ReferenceId>
          <FullCitation>Mansley MK, et al. Br. J. Pharmacol. (2010) pmid: 20880397</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="87">
          <ReferenceId>26267320</ReferenceId>
          <FullCitation>O'Neill D, et al. Oncotarget (2015) pmid: 26267320</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="88">
          <ReferenceId>18794135</ReferenceId>
          <FullCitation>Sherk AB, et al. Cancer Res. (2008) pmid: 18794135</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="89">
          <ReferenceId>23581296</ReferenceId>
          <FullCitation>Sommer EM, et al. Biochem. J. (2013) pmid: 23581296</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="90">
          <ReferenceId>17581577</ReferenceId>
          <FullCitation>David SS, et al. Nature (2007) pmid: 17581577</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="91">
          <ReferenceId>19953527</ReferenceId>
          <FullCitation>Molatore S, et al. Hum. Mutat. (2010) pmid: 19953527</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="92">
          <ReferenceId>19836313</ReferenceId>
          <FullCitation>Kundu S, et al. DNA Repair (Amst.) (2009) pmid: 19836313</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="93">
          <ReferenceId>20418187</ReferenceId>
          <FullCitation>D'Agostino VG, et al. DNA Repair (Amst.) (2010) pmid: 20418187</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="94">
          <ReferenceId>24310308</ReferenceId>
          <FullCitation>Hegde M, et al. Genet. Med. (2014) pmid: 24310308</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="95">
          <ReferenceId>22872101</ReferenceId>
          <FullCitation>Aretz S, et al. Eur. J. Hum. Genet. (2013) pmid: 22872101</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="96">
          <ReferenceId>18534194</ReferenceId>
          <FullCitation>Ali M, et al. Gastroenterology (2008) pmid: 18534194</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="97">
          <ReferenceId>24444654</ReferenceId>
          <FullCitation>Win AK, et al. Gastroenterology (2014) pmid: 24444654</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="98">
          <ReferenceId>19620482</ReferenceId>
          <FullCitation>Lubbe SJ, et al. J. Clin. Oncol. (2009) pmid: 19620482</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="99">
          <ReferenceId>19394335</ReferenceId>
          <FullCitation>Jones N, et al. Gastroenterology (2009) pmid: 19394335</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="100">
          <ReferenceId>21044966</ReferenceId>
          <FullCitation>Nielsen M, et al. J. Natl. Cancer Inst. (2010) pmid: 21044966</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="101">
          <ReferenceId>29165669</ReferenceId>
          <FullCitation>Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="102">
          <ReferenceId>12853198</ReferenceId>
          <FullCitation>Sampson JR, et al. Lancet (2003) pmid: 12853198</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="103">
          <ReferenceId>12606733</ReferenceId>
          <FullCitation>Sieber OM, et al. N. Engl. J. Med. (2003) pmid: 12606733</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="104">
          <ReferenceId>11818965</ReferenceId>
          <FullCitation>Al-Tassan N, et al. Nat. Genet. (2002) pmid: 11818965</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="105">
          <ReferenceId>21952991</ReferenceId>
          <FullCitation>Rennert G, et al. Cancer (2012) pmid: 21952991</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="106">
          <ReferenceId>16492928</ReferenceId>
          <FullCitation>Zhang Y, et al. Cancer Epidemiol. Biomarkers Prev. (2006) pmid: 16492928</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="107">
          <ReferenceId>21189386</ReferenceId>
          <FullCitation>von der Thüsen JH, et al. J. Clin. Oncol. (2011) pmid: 21189386</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="108">
          <ReferenceId>24420788</ReferenceId>
          <FullCitation>Casper M, et al. Fam. Cancer (2014) pmid: 24420788</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="109">
          <ReferenceId>20110747</ReferenceId>
          <FullCitation>Smith LM, et al. Pancreatology (2009) pmid: 20110747</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="110">
          <ReferenceId>15748635</ReferenceId>
          <FullCitation>Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="111">
          <ReferenceId>23875803</ReferenceId>
          <FullCitation>Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="112">
          <ReferenceId>12379884</ReferenceId>
          <FullCitation>Pfeifer GP, et al. Oncogene (2002) pmid: 12379884</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="113">
          <ReferenceId>25765070</ReferenceId>
          <FullCitation>Rizvi NA, et al. Science (2015) pmid: 25765070</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="114">
          <ReferenceId>24336570</ReferenceId>
          <FullCitation>Johnson BE, et al. Science (2014) pmid: 24336570</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="115">
          <ReferenceId>29452419</ReferenceId>
          <FullCitation>Choi S, et al. Neuro-oncology (2018) pmid: 29452419</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="116">
          <ReferenceId>23636398</ReferenceId>
          <FullCitation>Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="117">
          <ReferenceId>23447401</ReferenceId>
          <FullCitation>Briggs S, et al. J. Pathol. (2013) pmid: 23447401</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="118">
          <ReferenceId>24583393</ReferenceId>
          <FullCitation>Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="119">
          <ReferenceId>22810696</ReferenceId>
          <FullCitation>Nature (2012) pmid: 22810696</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="120">
          <ReferenceId>25568919</ReferenceId>
          <FullCitation>Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="121">
          <ReferenceId>27671167</ReferenceId>
          <FullCitation>Johnson DB, et al. Cancer Immunol Res (2016) pmid: 27671167</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="122">
          <ReferenceId>28835386</ReferenceId>
          <FullCitation>Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="123">
          <ReferenceId>29320474</ReferenceId>
          <FullCitation>Eroglu Z, et al. Nature (2018) pmid: 29320474</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="124">
          <ReferenceId>27903500</ReferenceId>
          <FullCitation>Shin DS, et al. Cancer Discov (2017) pmid: 27903500</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="125">
          <ReferenceId>29033130</ReferenceId>
          <FullCitation>Riaz N, et al. Cell (2017) pmid: 29033130</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="126">
          <ReferenceId>30309915</ReferenceId>
          <FullCitation>Cristescu R, et al. Science (2018) pmid: 30309915</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="127">
          <ReferenceId>30643254</ReferenceId>
          <FullCitation>Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="128">
          <ReferenceId>32919529</ReferenceId>
          <FullCitation>Lancet Oncol. (2020) pmid: 32919529</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="129">
          <ReferenceId>28420421</ReferenceId>
          <FullCitation>Chalmers ZR, et al. Genome Med (2017) pmid: 28420421</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="130">
          <ReferenceId>23945592</ReferenceId>
          <FullCitation>Alexandrov LB, et al. Nature (2013) pmid: 23945592</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="131">
          <ReferenceId>26343386</ReferenceId>
          <FullCitation>Shain AH, et al. Nat. Genet. (2015) pmid: 26343386</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="132">
          <ReferenceId>26960397</ReferenceId>
          <FullCitation>Madore J, et al. Clin. Cancer Res. (2016) pmid: 26960397</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="133">
          <ReferenceId>26559571</ReferenceId>
          <FullCitation>Shain AH, et al. N. Engl. J. Med. (2015) pmid: 26559571</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="134">
          <ReferenceId>31405947</ReferenceId>
          <FullCitation>Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="135">
          <ReferenceId>30785829</ReferenceId>
          <FullCitation>Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="136">
          <ReferenceId>29658845</ReferenceId>
          <FullCitation>Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="137">
          <ReferenceId>29657128</ReferenceId>
          <FullCitation>Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="138">
          <ReferenceId>29731394</ReferenceId>
          <FullCitation>Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="139">
          <ReferenceId>33558721</ReferenceId>
          <FullCitation>Rozeman EA, et al. Nat Med (2021) pmid: 33558721</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="140">
          <ReferenceId>32916128</ReferenceId>
          <FullCitation>Sharma P, et al. Cancer Cell (2020) pmid: 32916128</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="141">
          <ReferenceId>35355708</ReferenceId>
          <FullCitation>Ning B, et al. Front Pharmacol (2022) pmid: 35355708</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="142">
          <ReferenceId>31515453</ReferenceId>
          <FullCitation>Liu L, et al. Clin. Cancer Res. (2019) pmid: 31515453</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="143">
          <ReferenceId>9892009</ReferenceId>
          <FullCitation>Lebrun JJ, et al. Mol. Endocrinol. (1999) pmid: 9892009</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="144">
          <ReferenceId>16751101</ReferenceId>
          <FullCitation>Lin X, et al. Cell (2006) pmid: 16751101</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="145">
          <ReferenceId>23139211</ReferenceId>
          <FullCitation>Fleming NI, et al. Cancer Res. (2013) pmid: 23139211</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="146">
          <ReferenceId>12193595</ReferenceId>
          <FullCitation>Funaba M, et al. J. Biol. Chem. (2002) pmid: 12193595</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="147">
          <ReferenceId>8980228</ReferenceId>
          <FullCitation>Macías-Silva M, et al. Cell (1996) pmid: 8980228</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="148">
          <ReferenceId>16322555</ReferenceId>
          <FullCitation>Massagué J, et al. Genes Dev. (2005) pmid: 16322555</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="149">
          <ReferenceId>19531654</ReferenceId>
          <FullCitation>Matsuzaki K, et al. Cancer Res. (2009) pmid: 19531654</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="150">
          <ReferenceId>22539990</ReferenceId>
          <FullCitation>Wu Y, et al. PLoS ONE (2012) pmid: 22539990</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="151">
          <ReferenceId>25589618</ReferenceId>
          <FullCitation>Li YY, et al. Clin. Cancer Res. (2015) pmid: 25589618</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="152">
          <ReferenceId>25079317</ReferenceId>
          <FullCitation>Nature (2014) pmid: 25079317</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="153">
          <ReferenceId>22960745</ReferenceId>
          <FullCitation>Nature (2012) pmid: 22960745</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="154">
          <ReferenceId>25079552</ReferenceId>
          <FullCitation>Nature (2014) pmid: 25079552</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="155">
          <ReferenceId>22980975</ReferenceId>
          <FullCitation>Imielinski M, et al. Cell (2012) pmid: 22980975</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="156">
          <ReferenceId>8971158</ReferenceId>
          <FullCitation>Uchida K, et al. Cancer Res. (1996) pmid: 8971158</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="157">
          <ReferenceId>18948947</ReferenceId>
          <FullCitation>Ding L, et al. Nature (2008) pmid: 18948947</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="158">
          <ReferenceId>11391794</ReferenceId>
          <FullCitation>Boulay JL, et al. Genes Chromosomes Cancer (2001) pmid: 11391794</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="159">
          <ReferenceId>12967141</ReferenceId>
          <FullCitation>Xie W, et al. Cancer J () pmid: 12967141</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="160">
          <ReferenceId>17695423</ReferenceId>
          <FullCitation>Koumoundourou D, et al. Anticancer Res. () pmid: 17695423</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="161">
          <ReferenceId>11809701</ReferenceId>
          <FullCitation>Xie W, et al. Cancer Res. (2002) pmid: 11809701</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="162">
          <ReferenceId>17295676</ReferenceId>
          <FullCitation>Liapis G, et al. APMIS (2007) pmid: 17295676</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="163">
          <ReferenceId>17729405</ReferenceId>
          <FullCitation>Wu SK, et al. World J. Gastroenterol. (2007) pmid: 17729405</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="164">
          <ReferenceId>22275186</ReferenceId>
          <FullCitation>Xie W, et al. Head Neck (2013) pmid: 22275186</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="165">
          <ReferenceId>20462450</ReferenceId>
          <FullCitation>Mangone FR, et al. Mol. Cancer (2010) pmid: 20462450</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="166">
          <ReferenceId>17129361</ReferenceId>
          <FullCitation>Ehata S, et al. Cancer Sci. (2007) pmid: 17129361</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="167">
          <ReferenceId>19528470</ReferenceId>
          <FullCitation>Rausch MP, et al. Anticancer Res. (2009) pmid: 19528470</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="168">
          <ReferenceId>22015685</ReferenceId>
          <FullCitation>Shay JW, et al. Semin. Cancer Biol. (2011) pmid: 22015685</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="169">
          <ReferenceId>9282118</ReferenceId>
          <FullCitation>Shay JW, et al. Eur. J. Cancer (1997) pmid: 9282118</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="170">
          <ReferenceId>7605428</ReferenceId>
          <FullCitation>Kim NW, et al. Science (1994) pmid: 7605428</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="171">
          <ReferenceId>10647931</ReferenceId>
          <FullCitation>Hanahan D, et al. Cell (2000) pmid: 10647931</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="172">
          <ReferenceId>23348503</ReferenceId>
          <FullCitation>Horn S, et al. Science (2013) pmid: 23348503</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="173">
          <ReferenceId>23348506</ReferenceId>
          <FullCitation>Huang FW, et al. Science (2013) pmid: 23348506</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="174">
          <ReferenceId>23887589</ReferenceId>
          <FullCitation>Vinagre J, et al. Nat Commun (2013) pmid: 23887589</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="175">
          <ReferenceId>24691053</ReferenceId>
          <FullCitation>Pópulo H, et al. J. Invest. Dermatol. (2014) pmid: 24691053</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="176">
          <ReferenceId>24463461</ReferenceId>
          <FullCitation>Egberts F, et al. Melanoma Res. (2014) pmid: 24463461</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="177">
          <ReferenceId>24588324</ReferenceId>
          <FullCitation>Liau JY, et al. J. Cutan. Pathol. (2014) pmid: 24588324</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="178">
          <ReferenceId>24030752</ReferenceId>
          <FullCitation>Scott GA, et al. Mod. Pathol. (2014) pmid: 24030752</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="179">
          <ReferenceId>23799844</ReferenceId>
          <FullCitation>Griewank KG, et al. Br. J. Cancer (2013) pmid: 23799844</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="180">
          <ReferenceId>24569790</ReferenceId>
          <FullCitation>Heidenreich B, et al. Nat Commun (2014) pmid: 24569790</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="181">
          <ReferenceId>18067210</ReferenceId>
          <FullCitation>Zygouris P, et al. J BUON () pmid: 18067210</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="182">
          <ReferenceId>21993562</ReferenceId>
          <FullCitation>Law MH, et al. J. Invest. Dermatol. (2012) pmid: 21993562</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="183">
          <ReferenceId>23226346</ReferenceId>
          <FullCitation>Yin J, et al. PLoS ONE (2012) pmid: 23226346</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="184">
          <ReferenceId>21116649</ReferenceId>
          <FullCitation>Nan H, et al. Hum. Genet. (2011) pmid: 21116649</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="185">
          <ReferenceId>27245281</ReferenceId>
          <FullCitation>Nat Rev Clin Oncol (2017) pmid: 27245281</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="186">
          <ReferenceId>29249395</ReferenceId>
          <FullCitation>Duperret EK, et al. Mol Ther (2018) pmid: 29249395</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="187">
          <ReferenceId>25467017</ReferenceId>
          <FullCitation>Chiappori AA, et al. Ann Oncol (2015) pmid: 25467017</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="188">
          <ReferenceId>35940183</ReferenceId>
          <FullCitation>Dummer R, et al. Lancet Oncol (2022) pmid: 35940183</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="189">
          <ReferenceId>30918950</ReferenceId>
          <FullCitation>Hellmann MD, et al. Ann. Oncol. (2019) pmid: 30918950</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="190">
          <ReferenceId>27424159</ReferenceId>
          <FullCitation>Rosen LS, et al. Invest New Drugs (2016) pmid: 27424159</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="191">
          <ReferenceId>18390968</ReferenceId>
          <FullCitation>Adjei AA, et al. J. Clin. Oncol. (2008) pmid: 18390968</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="192">
          <ReferenceId>24947927</ReferenceId>
          <FullCitation>Zimmer L, et al. Clin. Cancer Res. (2014) pmid: 24947927</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="193">
          <ReferenceId>31436845</ReferenceId>
          <FullCitation>Goldinger SM, et al. Br. J. Dermatol. (2020) pmid: 31436845</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="194">
          <ReferenceId>22048237</ReferenceId>
          <FullCitation>Kirkwood JM, et al. Clin. Cancer Res. (2012) pmid: 22048237</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="195">
          <ReferenceId>23735514</ReferenceId>
          <FullCitation>Robert C, et al. Lancet Oncol. (2013) pmid: 23735514</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="196">
          <ReferenceId>24567366</ReferenceId>
          <FullCitation>Gupta A, et al. Ann. Oncol. (2014) pmid: 24567366</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="197">
          <ReferenceId>25344362</ReferenceId>
          <FullCitation>Tolcher AW, et al. Ann. Oncol. (2015) pmid: 25344362</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="198">
          <ReferenceId>30690294</ReferenceId>
          <FullCitation>Robert C, et al. Eur J Cancer (2019) pmid: 30690294</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="199">
          <ReferenceId>22805292</ReferenceId>
          <FullCitation>Falchook GS, et al. Lancet Oncol. (2012) pmid: 22805292</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="200">
          <ReferenceId>35272084</ReferenceId>
          <FullCitation>Salzmann M, et al. Eur J Cancer (2022) pmid: 35272084</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="201">
          <ReferenceId>36919691</ReferenceId>
          <FullCitation>Pigné T, et al. Melanoma Res (2023) pmid: 36919691</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="202">
          <ReferenceId>25542057</ReferenceId>
          <FullCitation>Coupe N, et al. Eur. J. Cancer (2015) pmid: 25542057</FullCitation>
          <Include>true</Include>
        </Reference>
      </References>
      <Signatures>
        <Signature>
          <ServerTime>2023-06-20 23:53:55</ServerTime>
          <OpName>Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director</OpName>
          <Text>Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director</Text>
        </Signature>
      </Signatures>
      <reportProperties>
        <reportProperty identifier="QualityControlMetrics" key="MedianCoverageValue">
          <value>819x</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="TumorMutationBurdenScore">
          <value>1 Muts/Mb</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="MicrosatelliteStatusScore">
          <value>0 fraction-unstable-loci</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="LossOfHeterozygosityScore">
          <value>Units Not Reported</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="BloodTumorMutationalBurdenScore">
          <value>Units Not Reported</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="TumorFractionScore">
          <value>Units Not Reported</value>
        </reportProperty>
      </reportProperties>
      <comments />
      <AAC>
        <Amendmends />
      </AAC>
    </FinalReport>
    <variant-report xmlns="http://foundationmedicine.com/compbio/variant-report-external" disease="SKIN" disease-ontology="Skin melanoma" flowcell-analysis="2000029547" gender="female" pathology-diagnosis="Melanoma, C43" percent-tumor-nuclei="20" pipeline-version="v3.23.0" purity-assessment="16.27" specimen="ORD-1648390-01*US1572225.01" study="CLINICAL-F1CDx v2" test-request="ORD-1648390-01" test-type="FoundationOneDx" tissue-of-origin="Lymph Node" xsi:schemaLocation="http://foundationmedicine.com/compbio/variant-report-external http://integration.foundationmedicine.com/reporting/variant-report-external-2.2.xsd">
      <samples>
        <sample bait-set="DX2" mean-exon-depth="825.11" name="SQ-US1572225.01-1" nucleic-acid-type="DNA" />
      </samples>
      <quality-control status="Pass" />
      <short-variants>
        <short-variant allele-fraction="0.593" cds-effect="1873G&gt;A" depth="602" equivocal="false" functional-effect="missense" gene="PARP1" percent-reads="59.3" position="chr1:226564877" protein-effect="A625T" status="unknown" strand="-" transcript="NM_001618">
          <dna-evidence sample="SQ-US1572225.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.398" cds-effect="892-2A&gt;G" depth="1078" equivocal="false" functional-effect="splice" gene="MUTYH" percent-reads="39.8" position="chr1:45797760" protein-effect="splice site 892-2A&gt;G" status="likely" strand="-" transcript="NM_001048171">
          <dna-evidence sample="SQ-US1572225.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4859" cds-effect="806C&gt;A" depth="601" equivocal="false" functional-effect="missense" gene="KDM5A" percent-reads="48.59" position="chr12:464388" protein-effect="T269N" status="unknown" strand="-" transcript="NM_001042603">
          <dna-evidence sample="SQ-US1572225.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4894" cds-effect="638_639insTGGCGGGGG" depth="141" equivocal="false" functional-effect="nonframeshift" gene="LTK" percent-reads="48.94" position="chr15:41804033" protein-effect="G213_A214insGGG" status="unknown" strand="-" transcript="NM_002344">
          <dna-evidence sample="SQ-US1572225.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.5058" cds-effect="8399C&gt;T" depth="1026" equivocal="false" functional-effect="missense" gene="SPEN" percent-reads="50.58" position="chr1:16261134" protein-effect="A2800V" status="unknown" strand="+" transcript="NM_015001">
          <dna-evidence sample="SQ-US1572225.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.1728" cds-effect="-146C&gt;T" depth="162" equivocal="false" functional-effect="promoter" gene="TERT" percent-reads="17.28" position="chr5:1295250" protein-effect="promoter -146C&gt;T" status="known" strand="-" transcript="NM_198253">
          <dna-evidence sample="SQ-US1572225.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4543" cds-effect="263A&gt;G" depth="656" equivocal="false" functional-effect="missense" gene="PIK3C2G" percent-reads="45.43" position="chr12:18435278" protein-effect="E88G" status="unknown" strand="+" transcript="NM_004570">
          <dna-evidence sample="SQ-US1572225.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.5248" cds-effect="29_30delTG" depth="505" equivocal="false" functional-effect="frameshift" gene="PRDM1" percent-reads="52.48" position="chr6:106534456" protein-effect="V10fs*10" status="likely" strand="+" transcript="NM_001198">
          <dna-evidence sample="SQ-US1572225.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.164" cds-effect="182A&gt;G" depth="628" equivocal="false" functional-effect="missense" gene="NRAS" percent-reads="16.4" position="chr1:115256529" protein-effect="Q61R" status="known" strand="-" transcript="NM_002524">
          <dna-evidence sample="SQ-US1572225.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.1467" cds-effect="1351G&gt;A" depth="518" equivocal="false" functional-effect="missense" gene="SNCAIP" percent-reads="14.67" position="chr5:121776378" protein-effect="D451N" status="unknown" strand="+" transcript="NM_005460">
          <dna-evidence sample="SQ-US1572225.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4798" cds-effect="3820G&gt;A" depth="619" equivocal="false" functional-effect="missense" gene="ALK" percent-reads="47.98" position="chr2:29432668" protein-effect="A1274T" status="unknown" strand="-" transcript="NM_004304">
          <dna-evidence sample="SQ-US1572225.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.054" cds-effect="1010C&gt;T" depth="648" equivocal="false" functional-effect="missense" gene="DNMT3A" percent-reads="5.4" position="chr2:25470464" protein-effect="S337L" status="unknown" strand="-" transcript="NM_022552">
          <dna-evidence sample="SQ-US1572225.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.1077" cds-effect="2941C&gt;T" depth="483" equivocal="false" functional-effect="missense" gene="PIK3C2G" percent-reads="10.77" position="chr12:18656262" protein-effect="R981C" status="unknown" strand="+" transcript="NM_004570">
          <dna-evidence sample="SQ-US1572225.01-1" />
        </short-variant>
      </short-variants>
      <copy-number-alterations>
        <copy-number-alteration copy-number="0" equivocal="false" gene="SGK1" number-of-exons="14 of 17" position="chr6:134491405-134498960" ratio="0.82" status="known" type="loss">
          <dna-evidence sample="SQ-US1572225.01-1" />
        </copy-number-alteration>
        <copy-number-alteration copy-number="0" equivocal="false" gene="SMAD2" number-of-exons="2 of 10" position="chr18:45374845-45377733" ratio="0.62" status="known" type="loss">
          <dna-evidence sample="SQ-US1572225.01-1" />
        </copy-number-alteration>
      </copy-number-alterations>
      <rearrangements />
      <biomarkers>
        <microsatellite-instability status="MSS" />
        <tumor-mutation-burden score="1.21" status="low" unit="mutations-per-megabase" />
      </biomarkers>
      <non-human-content />
    </variant-report>
  </rr:ResultsPayload>
</rr:ResultsReport>
